Introduction
Gene therapy with human adenoviral vectors is under investigation as an alternative approach to treat cancer. Replication-defective adenoviral gene delivery vectors have so far shown only modest antitumor efficacy, partly because of poor penetration capacity in solid tumor masses. To overcome this limitation, conditionally replicating adenoviruses (CRAds) were developed and explored as novel anticancer agents. [1] [2] [3] CRAds replicate only in cancer cells and destroy these cells through the natural process of adenoviral replication. In addition, the generated progeny viruses released from infected and lysed cancer cells may infect neighboring tumor cells. Via multiple cycles of lytic replication and lateral spread, more pronounced antitumor effect is accomplished. Unfortunately, however, the efficacy of CRAds as monotherapeutic agents in clinical trials has so far been limited. 4, 5 Treatment modalities in which CRAd virotherapy was combined with a conventional chemotherapeutic agent such as cisplatin, 5-FU or paclitaxel were significantly more effective than treatment with either agent alone. [6] [7] [8] This synergy between CRAds and chemotherapy warranted studies into combinations of CRAds with the more selective gene-directed enzyme prodrug therapy (GDEPT). In GDEPT, tumor cells are transduced with an expression vector encoding an enzyme that converts a nontoxic prodrug into an active drug. After systemic administration of the prodrug, this will lead to local prodrug activation at the tumor site, resulting in tumor-specific toxicity. Arming CRAds with a prodrug-activating gene might thus result in augmented antitumor effects similar to the combined effect of CRAds and chemotherapy, but with less systemic toxicity. In addition, the CRAd may be considered as a very potent enzyme expression vector as it is amplified in infected cells. Higher levels of prodrugconverting enzyme in the tumor should produce higher local toxic drug concentrations, thereby causing a more effective GDEPT.
Several prodrug-converting enzymes, including carboxylesterase (CE) that activates the prodrug CPT-11 into the toxic drug SN-38 and Herpes Simplex Virus thymidine kinase (HSV-TK) that converts the prodrug ganciclovir (GCV) into its active metabolite and nitroreductase that activates CB1954, have already been incorporated into the genome of replication-competent adenoviruses. [9] [10] [11] [12] [13] [14] [15] Only in some cases, addition of the prodrug increased the oncolytic potency as expected. 9, 10, 12 Remarkably, in all successful studies E1B-deleted CRAds with severely compromised replication capacity were used.
Since then, much more potent CRAds have been constructed. One of these is AdD24, or dl922-947, that contains a subtle deletion in the E1A region that abolishes binding of E1A to members of the Rb family of pocket proteins. 16, 17 As AdD24 is defective in sequestering pRb from E2F, its replication depends on E2F being released through other means. This is the case in most, if not all, cancer cells through pRb deficiency, pRb hyperphosphorylation, or pRb sequestration by cellular or viral proteins associated with malignancy. Indeed, it was demonstrated that AdD24 replicates in and lyses both dividing and nondividing tumor cells with high efficiency, whereas cancer cells with restored pRb activity were resistant to the virus in vitro. 16 Although AdD24 was not entirely cancer-specific, as it was also shown to replicate in proliferating normal cell cultures and in human brain explants, 17, 18 the CRAd did not replicate in growth-arrested normal cell cultures, 17 suggesting relative safety in normal tissues. The virus was effective against a range of cancer cells in vitro and in vivo, exhibiting a potency superior to that of an E1B-deleted CRAd and in some cancer types even to that of wild-type adenovirus. 17 This led us to investigate if combining the more powerful AdD24 virotherapy with GDEPT using the HSV-TK/GCV or CE/CPT-11 paradigms would further increase its anticancer efficacy.
Results

TK/GCV GDEPT decreases the oncolytic potency of AdD24 against colon cancer cells
Human colon cancer cell lines SW1398, WiDr and Colo205 were infected with a dual virus mixture consisting of replication-deficient AdCMVHSV-TK and the CRAd AdD24 and treated with the prodrug GCV ( Figure 1 ). In this system, the prodrug-converting enzyme is expressed in the context of CRAd replication. As controls, cells were treated with GCV only, infected with AdD24 and treated with prodrug or transduced with AdCMVHSV-TK and treated with GCV. After 6 days of culture, the viability of the cells was determined by WST-1 analysis.
In all three colon cancer cell lines, treatment with GCV had no effect on viability, while transduction with AdCMVHSV-TK and GCV treatment was cytotoxic at the higher concentrations of GCV, suggesting GCV activation. Infection with AdD24 induced dose-dependent cell death that was not affected by GCV treatment. Sensitivity of the cells to AdCMVHSV-TK/GCV treatment was not affected by co-infecting the cells with AdD24. However, at concentrations of GCV below 10 mM, a significant reduction in AdD24 oncolytic toxicity on AdCMVHSV-TK-transduced cells became apparent. Thus, the combination of AdD24 replication and HSV-TK/GCV GDEPT did not lead to enhanced colon cancer cell death. Instead, at low GCV concentrations, HSV-TK/ GCV GDEPT decreased the anticancer effect of AdD24.
sCE2/CPT-11 GDEPT enhances the oncolytic potency of AdD24 against colon cancer cells Similar combination experiments as above were carried out with mixtures of replication-deficient Ad-sCE2 expressing a secreted variant of human CE and AdD24 plus CPT-11 prodrug (Figure 2 ). CPT-11 was toxic to the cells at concentrations above 1 mM and Ad-sCE2 sensi- Figure 1 Exogenous expression of TK combined with GCV treatment decreases the oncolytic potency of AdD24 against colon cancer cells. Three colon cancer cell lines (SW1398, WiDr and Colo205) were infected with AdCMVHSV-TK at an MOI of 600, or with AdD24 at an MOI of 1 or 10, or with dual virus mixtures and treated with GCV as indicated. After 6 days, the viability of the cells was determined with WST-1 and results are expressed as % of the untreated control cells. In all the three cell lines, combination treatment consisting of AdCMVHSV-TK, Ad524 and nontoxic concentrations of GCV was less effective than AdD24 treatment only. At higher concentrations of GCV, the efficacy of dual virus mixture therapy was comparable to AdCMVHSV-TK/ GCV only.
CRAd with GDEPT for colon cancer D Oosterhoff et al tized the cells to CPT-11 at lower concentrations. CPT-11 treatment did not affect the oncolytic function of AdD24. Co-infection with AdD24 and Ad-sCE2 without CPT-11 treatment was as toxic as AdD24 infection alone. Most importantly, AdD24 plus Ad-sCE2/CPT-11 treatment showed a CPT-11 dose-dependent increase in cytotoxicity. At 0.1-1 mM CPT-11, AdD24 plus GDEPT was as effective or more effective than AdD24 virotherapy at a 10-times higher viral dose. Next, we conducted similar combination experiments with sCE2/CPT-11 and Ad5-D24.E3. In contrast to AdD24, Ad5-D24.E3 contains an intact E3 region, which encodes the adenoviral death protein that promotes cytolysis. 19 In addition, E3 proteins contribute to virotherapy efficacy in vivo. 20 Consequently, Ad5-D24.E3 is more potent than AdD24. Combination experiments showed that the efficacy of Ad5-D24.E3 could also be further improved by expression of sCE2 and treatment with nontoxic doses of CPT-11 ( Figure 3 ). Hence, in contrast to HSV-TK/GCV GDEPT, sCE2/CPT-11 GDEPT enhanced the oncolytic potency of strong AdD24-type CRAds.
Construction and characterization of sCE2 expressing CRAd Ad5-D24.E3-sCE2 Based on the observations described above, we decided to construct an Ad5-D24.E3-derived CRAd expressing sCE2, which is schematically shown in Figure 4a . 
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Insertion of the sCE2 expression cassette into the adenoviral genome, creating a virus with an approximately 108% wild-type genome size, did not affect propagation efficiency (not shown). Proper expression of sCE2 by the new CRAd Ad5-D24.E3-sCE2 was tested by infecting SW1398 cells at low multiplicity of infection (MOI) and measuring CE activity in the supernatant of infected cells at different time points after infection. As expected, extracellular CE activity increased in time, as the CRAd replicated and spread in the culture ( Figure  4b ). In the same experiment, SW1398 cells were transduced with the replication-deficient adenovirus Ad-sCE2 at various MOIs. As can be seen in Figure 4c , a more than 300-fold higher MOI of the replicationdeficient vector was needed to obtain comparable CE activity in the supernatant at day 5 after transduction.
To analyze the effect of sCE2/CPT-11 enzyme prodrug therapy on viral replication, Colo205 and WiDr cells were infected with Ad5-D24.E3-sCE2 at low MOI and the viral titer was determined 5 and 12 days later. As can be seen in Figure 5 , CPT-11 treatment decreased the viral output from Ad5-D24.E3-sCE2-infected cells up to 300-fold. Virus expansion from day 5 to 12 post-infection was decreased by 10-fold. Thus, sCE2/CPT-11 GDEPT inhibited CRAd propagation.
Ad5-D24.E3-sCE2 exhibits enhanced cytotoxicity against colon cancer cell lines when combined with CPT-11 treatment
To determine the cytotoxic potency of Ad5-D24.E3-sCE2, human colon cancer cell lines were infected with Ad5-D24.E3-sCE2 or with the parent control virus Ad5-D24.E3 and treated with CPT-11. After 6 days, viability of the cells was determined by WST-1 assay. Figure 6 shows that, in the absence of CPT-11, sCE2 transgene expression did not change CRAd oncolytic potency on Colo205 and SW1398 cells and only slightly enhanced killing of WiDr cells. Most importantly, Ad5-D24.E3-sCE2, but not Ad5-D24.E3, sensitized colon cancer cells to CPT-11. At an MOI at which Ad5-D24.E3-sCE2 and its parent Ad5-D24.E3 were only mildly toxic, addition of a nontoxic concentration of 1 mM CPT-11 killed 60-80% of Ad5-D24.E3-sCE2-infected colon cancer cells.
To study oncolytic replication of the new CRAd Ad5-D24.E3-sCE2 in the continued presence of CPT-11, colon cancer cell lines were infected with Ad5-D24.E3-sCE2 at low MOI and cultured in the presence of a nontoxic concentration of CPT-11 or in plain medium. At several days post-infection, cells that had survived the treatment were stained with crystal violet. This revealed a progressive destruction of all monolayers by replicating Ad5-D24.E3-sCE2. After 11 days, surviving cells were stained with crystal violet. Figure 7 shows more prominent plaques indicative of lytic replication in the absence of CPT-11, suggesting CRAd propagation inhibition by sCE2/CPT-11 GDEPT. However, it can also be seen that Ad5-D24.E3-sCE2 eradicated monolayers of all three colon cancer cell lines more effectively in the presence of a nontoxic dose of CPT-11. Hence, despite the inhibitory influence of sCE2/CPT-11 GDEPT on CRAd propagation, CRAd/GDEPT combination therapy was still more effective than either treatment alone. CRAd
Discussion
Combining CRAd virotherapy with GDEPT is under evaluation for effective anticancer treatment. Previously, HSV-TK/GCV GDEPT has been tested in the context of E1B-55 kDa-deleted CRAds 9,10 or wild-type adenovirus. 11, 13, 14 In general, these studies showed that HSV-TK/GDEPT primarily enhanced the oncolytic potency of severely attenuated E1B-55 kDa-deleted CRAds, whereas the antitumor efficacy of more potent wild-type viruses decreased when combined with TK/GCV GDEPT. Interestingly, Nanda et al 21 found that, although TK/ GCV treatment completely abrogated wild-type adenovirus replication when administered concomitantly, it significantly enhanced the oncolytic potency of wild-type adenovirus when GCV administration was started 1 or 2 days after virus injection. 21 Virotherapy has also been combined with HSV-TK/GCV and cytosine deaminase (CD)/5-FC double GDEPT. Freytag et al 22 showed that an E1B-55 kDa-deleted CRAd expressing a fusion gene consisting of CD and TK was quite effective in killing cancer cells in vitro when combined with GCV or 5-FC, an effect that could be further augmented by irradiation. Interestingly, these effects occurred at prodrug concentrations that inhibited adenovirus replication, suggesting that the CRAd acted merely as an effective prodrug- CRAd with GDEPT for colon cancer D Oosterhoff et al converting gene transfer vector. Furthermore, combination therapy of colon cancer cells with an E1B-55 kDadeleted CRAd expressing the enzyme nitroreductase and the prodrug CB1954 also demonstrated that prodrug treatment can inhibit viral replication. 15 Recently, Stubdal et al 12 incorporated the rabbit CE gene into an E1B-deleted CRAd. In vitro, this virus exhibited increased toxicity on a colon carcinoma cell line in the presence of CPT-11 compared to control virus. However, treatment with CPT-11 did not enhance survival of mice carrying CRAd-CE-injected subcutaneous colon cancer xenografts. In the aggregate, previous results suggest that arming CRAds with transgenes for GDEPT can improve their oncolytic potential. However, careful evaluation of CRAd efficacy enhancing versus abrogating activities of GDEPT is needed. Apparently, in the context of virotherapy, there is a delicate balance between GDEPTinduced cancer cell death and GDEPT-mediated impairment of viral replication.
Since the aim of arming CRAds with therapeutic genes such as those encoding prodrug-converting enzymes is to augment their anticancer potency, studies into combining CRAds and GDEPT are most useful if they are performed with the most powerful types of CRAds. Therefore, we studied whether the CRAd AdD24, which is much more potent than E1B-deleted CRAds, 17 could be further improved by combinations with HSV-TK/GCV or sCE2/CPT-11 GDEPT. To this end, we used an in vitro adenovirus-mixing model where cells are transduced with AdD24 and a replication-deficient adenovirus expressing TK or sCE2. Using this model, we could select a suitable CRAd-GDEPT combination prior to actually constructing the CRAd expressing the prodrugconverting enzyme. Hence, the mixing model could prove useful for quick evaluation of other CRAd-GDEPT systems as well.
We found that HSV-TK/GCV GDEPT decreased treatment efficacy, which was in line with earlier studies showing that HSV-TK/GCV GDEPT also did not work in combination with wild-type adenovirus. 11, 13, 14 It can thus be concluded that GCV/TK GDEPT is not suitable to improve the efficacy of potent CRAds. In contrast, expression of sCE2 in the context of AdD24 replication combined with CPT-11 treatment increased the efficacy of virotherapy. This was also true for Ad5-D24.E3, a more potent AdD24 variant that retains the E3 region. 19 Therefore, we constructed Ad5-D24.E3-sCE2, a derivative of Ad5-D24.E3 expressing sCE2. This new CRAd differs materially from the previously described E1B-deleted CE-expressing CRAd ONYX-713 12 in that Ad5-D24.E3-sCE2 is a derivative from the more potent CRAd AdD24 and that it encodes a secreted form of human CE-2 instead of an intracellular form of rabbit CE.
Ad5-D24.E3-sCE2 replicated efficiently in human colon cancer cells and expressed high levels of functional sCE2 protein. In the presence of CPT-11, however, Ad5-D24.E3-sCE2 viral propagation rate was markedly decreased. This observation can perhaps be explained by the fact that the active drug SN-38 that is produced through sCE2-mediated conversion of CPT-11 inhibits topoisomerase I, which has been demonstrated essential for viral replication. [23] [24] [25] Nevertheless, sCE2/GCV GDEPT enhanced the efficacy of Ad5-D24.E3 against colon cancer cells. This increased efficacy of combination treatment is probably due to a strong bystander effect of the secreted prodrug-converting enzyme causing toxicity of extracellularly converted CPT-11 to uninfected neighboring cells. Such a bystander effect will contribute to the observed virus propagation inhibition, as cells already affected by SN-38 prior to Ad5-D24.E3-sCE2 infection will not support CRAd replication. Therefore, treatment regimens might perhaps be optimized by delayed administration of CPT-11.
Several further improvements to CRAd-sCE2/CPT-11 treatment can be foreseen. First, double E1A mutant CRAds have been described with a more stringent replication pattern than AdD24. 26, 27 The selectivity of the CE-expressing CRAd might thus be improved by using such viruses as backbones. Second, selective expression of the transgene in cancer cells could contribute to diminishing GDEPT cytotoxicity to nonmalignant cells. This can be accomplished by driving the expression of the prodrug-converting enzyme by a cancer cell-specific promoter or by the endogenous adenovirus major late promoter. 28 Third, leakage of sCE2 from the tumor, potentially causing systemic toxicity, can be prevented by constructing a fusion protein consisting of sCE2 and an scFv antibody directed to a tumor antigen. 29 In conclusion, we have demonstrated that, in contrast to HSV-TK/GCV GDEPT, sCE2/CPT-11 GDEPT can be used to augment the anticancer potency of already very effective AdD24-type CRAds. This warrants further evaluation of CRAd plus sCE2/CPT-11 GDEPT strategies for colorectal cancer.
Materials and methods
Cells and culture conditions
The colon cancer cell lines SW1398, Colo205 and WiDr and the lung cancer cell line A549 were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 50 IU/ml penicillin and 50 mg/ml streptomycin (Invitrogen, Breda, The Netherlands), at 371C in a 5% CO 2 humidified atmosphere. 293 (ATCC, Manassas, VA, USA) and 911 (Introgene, Leiden, The Netherlands) cells were maintained in DMEM supplemented with 10% FCS, 50 IU/ml penicillin, 50 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen).
Recombinant adenoviruses
The replication-deficient adenoviral vectors Ad-sCE2 30 and AdCMVHSV-TK 31 that express cytomegalovirus immediate early promoter-driven secreted human liver carboxylesterase-2 (sCE2) and HSV-TK, respectively, have been described previously. The conditionally replication-competent adenovirus AdD24 containing a 24 bp deletion in the CR2 domain of the E1A region, resulting in selective replication in pRb-mutated cells, 16 has been described previously. 32 The CRAd Ad5-D24.E3 has the same deletion in E1A; but retains the entire E3 region. 19 To construct the AdD24 CRAd with an expression cassette for sCE2, the CMV-sCE2 expression cassette was amplified from pSTCF-sCE2 33 by PCR with sense primer 5 0 -CAGCATGCTATGGTCGACTCTCAGTACAA TCTGCTC-3 0 and antisense primer 5'-AAGCCATAGA GCCCACCGCATCC-3 0 . The resulting fragment was
CRAd with GDEPT for colon cancer D Oosterhoff et al digested with SphI that cuts in the sense primer (italic) and four nucleotides adjacent to the antisense primerannealing site, and inserted into SphI digested pABS.4 (Microbix, Biosystems, Toronto, Canada) to generate pABS.4-sCE2. Functional expression of sCE2 was confirmed following transient transfection of the plasmid into COS-7 cells. At 2 days after transfection, supernatants were harvested and CE activity was measured by pNpAc conversion as described previously. 33 To construct a GATEWAY compatible entry vector, pABS.4-sCE2 was digested with NruI and KpnI and ligated into EcoRV/KpnI digested pENTR-2B (Invitrogen) creating pENTR-sCE2. The GATEWAY system compatible adenoviral shuttle vector pEndK/DEST-R carrying the DEST cassette in the adenovirus genome between the E4 region and the right-hand ITR has been described previously. 34 The sCE2 expression cassette of pENTR-sCE2 was transported into this pEndK/DEST-R via an LR Gateway in vitro recombination reaction (Invitrogen) according to the manufacturer's protocol, generating pEndK-sCE2-R containing the CMV promoter and sCE2 in the rightward orientation of the adenoviral genome.
An Ad5-D24.E3 derivative CRAd-expressing sCE2 was generated by homologous recombination in Escherichia coli BJ5183 between Ad5-D24.E3 viral DNA and EcoRVdigested pEndK-sCE2-R to form plasmid pAd5-D24.E3-sCE2-R. This plasmid was digested with PacI to release the full-length adenoviral DNA from the plasmid backbone and was transfected into 293 cells. The CRAd Ad5-D24.E3-sCE2 was harvested and further propagated on A549 cells. The E1A-D24 mutation and the sCE2 insertion were confirmed by PCR on the final products and functional plaque-forming units (PFU) titers were determined by limiting-dilution plaque titration on 293 cells according to standard techniques. All infections were normalized on the basis of PFU titers.
CE activity in the supernatant of adenovirus-infected cells SW1398 cells were infected with Ad5-D24.E3-sCE2 at a MOI of 0.3 or with a range of MOIs of Ad-sCE2. At different time points after infection, the supernatants were harvested and analyzed for esterase activity. Supernatant aliquots were incubated in 50 mM HEPES (pH 7.4) containing 3 mM para-nitrophenyl acetate, an esterase substrate, and conversion was monitored at 420 nm for 5 min on a Bio-Rad microplate reader. Data were expressed as mmol p-nitrophenol produced per milliliter of culture media.
Ad5-D24.E3-sCE2 burst size in the presence of CPT-11
WiDr and Colo205 cells were seeded at 1 Â 10 5 cells/well in 24-well plates and cultured overnight. The next day, the cells were infected with Ad5-D24.E3-sCE2 at MOI 0.01 and cultured with or without 1 mM CPT-11. After 5 and 12 days, cells were harvested in the culture medium and subjected to three rounds of freeze/thawing to release viral particles. Titers were determined using the Adeno-Xt Rapid Titer Kit (Becton Dickinson) and a modified protocol. Briefly, 911 cells were plated (2.5 Â 10 4 cells/well) in a 96-well plate. The next day, cells were infected in triplicate with serially diluted Ad5-D24.E3-sCE2 samples. After 2 days, cells were fixed with methanol and stained with mouse antihexon antibody, HRP-labeled rat anti-mouse antibody and DAB substrate. Hereafter, hexon-positive cells were counted in wells from at least three virus dilutions and viral titers were calculated from linear regression analyses.
WST-1 cell viability assay on colon cancer cells treated with adenovirus and GDEPT colon carcinoma cells 1 Â 10 4 /well were seeded in a 96-well microtiter plate (Greiner). After 24 h, the medium was replaced with a dual virus mixture consisting of Ad-sCE2 or AdCMVHSV-TK at an MOI of 600, with AdD24 at an MOI of 1 or 10 or Ad5-D24.E3 or Ad5-D24.E3-sCE2 at an MOI of 1. Simultaneously, a concentration range of the prodrugs CPT-11 (Aventis, Strasbourg, France) or GCV (Roche Diagnostics, Almere, The Netherlands) was added. After 6 days of culture, the viability of the cells was determined by performing a WST-1 conversion assay. For that, the culture medium was removed and replaced by 100 ml 10% WST-1 (Roche Diagnostics) in culture medium. After 60-90 min incubation at 371C, A 450 was measured on a Bio-Rad microplate reader. WST-1 conversion was expressed as percentage of the conversion by uninfected, untreated control cells after subtraction of background values in the absence of cells.
Crystal violet cytotoxicity assay on CRAd/GDEPT-treated colon cancer cells
Cells were seeded at 1 Â 10 5 cells/well in 24-well plates and cultured overnight. The next day, the cells were infected with Ad5-D24.E3-sCE2 at the indicated MOI. Hereafter, cells were cultured with or without 1 mM CPT-11, with 50% medium changes every 2-3 days. At day 11 after infection, cells were washed with PBS and fixed for 10 min at room temperature in 4% formaldehyde in PBS. Cells were stained using 1% crystal violet dye in 70% ethanol for 15 min at room temperature. After several washes with water, the culture plates were air dried and scanned on a Bio-Rad GS-690 imaging densitometer.
